- Home
- SAVA vs NMI Comparison
SAVA vs NMI Comparison
Compare SAVA & NMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SAVA | NMI |
|---|---|---|
| Founded | 1998 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 96.1M | 111.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SAVA | NMI |
|---|---|---|
| Price | $2.13 | $10.18 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | ★ 772.9K | 28.4K |
| Earning Date | 03-02-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.10% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.15 | $8.30 |
| 52 Week High | $4.98 | $10.05 |
Technical Indicators
Market Signals| Indicator | SAVA | NMI |
|---|---|---|
| Relative Strength Index (RSI) | 47.99 | 57.55 |
| Support Level | $2.04 | $10.06 |
| Resistance Level | $2.22 | $10.25 |
| Average True Range (ATR) | 0.11 | 0.11 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 62.86 | 79.07 |
Price Performance
Historical ComparisonAbout SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.
About NMI Nuveen Municipal Income Fund Inc.
Nuveen Municipal Income Fund Inc is a diversified, closed-end management investment company. The Fund's investment objective is to provide a high level of current income exempt from federal income tax, which it seeks to achieve by investing mainly in a diversified portfolio of tax-exempt municipal obligations.